The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Metastatic breast cancer remains a leading cause of cancer death, with current therapies often failing to achieve cures.
• Tumor cell migration and invasion are critical steps in metastasis, driven by actin cytoskeletal reorganization.
• The mechanisms by which migratory cancer cells colonize distant tissues to form macrometastases are not fully understood.

Purpose of the Study:

• To investigate the role of E6-associated protein (E6AP) in breast cancer metastasis.
• To elucidate the molecular mechanisms by which E6AP regulates cancer cell invasion and colonization.
• To determine the prognostic significance of E6AP expression in breast cancer patients.

Main Methods:

• Utilized mouse models of breast cancer metastasis to assess the function of E6AP.
• Analyzed patient data to correlate E6AP expression levels with clinical prognosis.
• Investigated the regulation of actin cytoskeleton remodeling and Rho GTPase activity by E6AP, focusing on its interaction with ECT2.

Main Results:

• E6AP suppresses breast cancer invasiveness, colonization, and metastasis in preclinical models.
• Loss of E6AP expression is associated with poor prognosis in breast cancer patients, particularly in basal-type cancers.
• E6AP negatively regulates ECT2, a guanine nucleotide exchange factor (GEF), by promoting its ubiquitination and proteasomal degradation, thereby controlling Rho GTPase activation and actin remodeling.
• High ECT2 expression predicts poor prognosis in breast cancer patients.

Conclusions:

• E6AP acts as a suppressor of breast cancer metastasis by controlling actin cytoskeleton remodeling via the ECT2/Rho GTPase pathway.
• E6AP represents a novel suppressor of metastasis with significant prognostic implications.
• Targeting ECT2 may offer a therapeutic strategy for patients with metastatic breast cancer.